Verification evidence is still being completed.
PDF / print export
Diamyd Medical
Stockholm, Sweden
- Verified lead
- Ulf Hannelius
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- President and CEO
- 2026 technical specialization
- Type 1 Diabetes, Precision Immunotherapy, Autoimmune Disease, Clinical Development, and Biotech Platform Development
- Review cycle
- May 2026
- Full address
- Diamyd Medical AB (publ), Kungsgatan 29, SE-111 56 Stockholm, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Diamyd Medical contact page confirming the Stockholm address.
- Editorial note
- Diamyd Medical is published because official company materials confirm current leadership, Stockholm operating address, and a real precision-diabetes therapeutics platform.
Type 1 Diabetes, Precision Immunotherapy, Autoimmune Disease, Clinical Development, and Biotech Platform Development
Official leadership disclosure, Official Stockholm address disclosure, Clinical-stage precision-medicine platform claim
Diamyd Medical is published because official company materials confirm current leadership, Stockholm operating address, and a real precision-diabetes therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Stockholm, Sweden
Diamyd Medical
Type 1 Diabetes, Precision Immunotherapy, Autoimmune Disease, Clinical Development, and Biotech Platform Development · Clinical-stage therapeutics platform
Diamyd Medical runs precision immunotherapy development, clinical diabetes programs, and biotech platform development in Stockholm, Sweden.
- Lead
- Ulf Hannelius (verified ↗)
- Address
- Diamyd Medical AB (publ), Kungsgatan 29, SE-111 56 Stockholm, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Precision Immunotherapy Development · Clinical Diabetes Programs · Biotech Platform Development
- Founded
- 1996
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Ulf Hannelius
President and CEO
Full addressDiamyd Medical AB (publ), Kungsgatan 29, SE-111 56 Stockholm, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Diamyd Medical contact page listing the Stockholm visiting address.
Open sourceClinical-stage therapeutics platform
Stockholm, Sweden. Type 1 Diabetes, Precision Immunotherapy, Autoimmune Disease, Clinical Development, and Biotech Platform Development. Review completed on 21 Mar 2026.
Swedish corporate and clinical-development oversight
Official leadership disclosure, Official Stockholm address disclosure, Clinical-stage precision-medicine platform claim
Type 1 Diabetes, Precision Immunotherapy, Autoimmune Disease, Clinical Development, and Biotech Platform Development
Diamyd Medical is published because official company materials confirm current leadership, Stockholm operating address, and a real precision-diabetes therapeutics platform.
Editorial note
Diamyd Medical is published because official company materials confirm current leadership, Stockholm operating address, and a real precision-diabetes therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Precision Immunotherapy Development
Clinical Diabetes Programs
Biotech Platform Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Clinical development workflow
Precision-medicine infrastructure
Program management systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Diamyd Medical located?
- Diamyd Medical operates from Diamyd Medical AB (publ), Kungsgatan 29, SE-111 56 Stockholm, Sweden, Stockholm, Sweden.
- Who runs Diamyd Medical?
- Diamyd Medical is led by Ulf Hannelius, President and CEO. Verified 21 Mar 2026.
- What does Diamyd Medical do?
- Diamyd Medical runs precision immunotherapy development, clinical diabetes programs, and biotech platform development in Stockholm, Sweden. Core capabilities: Precision Immunotherapy Development, Clinical Diabetes Programs, Biotech Platform Development.
Editorial context
Related technical briefs
Briefs that name Stockholm as a covered market or city.